Lv5
809 积分 2024-07-03 加入
[Guidelines on clinical practice of molecular tests in non-small cell lung cancer in China (2024 version)]
1天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
9天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
22天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
26天前
已完结
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
26天前
已完结
Nivolumab for recurrent squamous-cell carcinoma of the head and neck
28天前
已完结
Epidermal Growth Factor Receptor Biology in Head and Neck Cancer
29天前
已完结
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
1个月前
已完结
Comparison of Second-Line Treatments of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
1个月前
已完结
Comparison of Second-Line Treatments of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
1个月前
已关闭
A game theoretic approach for analyzing financial intervention models in dairy green supply chains with freshness-keeping effort
Real-life use of letermovir prophylaxis for cytomegalovirus in heart transplant recipients
皖公网安备34019202002308
